Drugs / VC-02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03162926 | Jul 2017 → Feb 2018 | type 1 diabetes mellitus | ViaCyte | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03163511 | Jul 2017 → Oct 2023 | type 1 diabetes mellitus | ViaCyte | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-07-31 | Hopstem Biotechnology Inc. | Results 【七月精选】领域最新进展 hopstem.com ↗
结果显示胰岛祖细胞成功定植在患者体内并能够产生和分泌胰岛素，临床相关的糖应答C肽水平相应升高，治疗改善了血糖控制，并且无严重不良事件的报告。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-31 | Hopstem Biotechnology Inc. | 【七月精选】领域最新进展 hopstem.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VC-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03162926 ↗ |
| Known as | PEC-Direct | “VC-02 Combination Product (aka PEC-Direct)” NCT03162926 ↗ |
| Modality | Cell therapy | “experimental cell replacement therapy intended to provide a functional cure” NCT03163511 ↗ |
| Route | Subcutaneous | “implanted subcutaneously” NCT03162926 ↗ |